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Background
On-site monitoring is a common but time-consuming
and expensive activity, with little evidence that it is
worthwhile. Centralised statistical monitoring (CSM) is
a much cheaper alternative, where data checks are per-
formed by the co-ordinating centre, reducing the need
to visit every site. Although some publications have out-
lined possible methods, few have applied them to data
from real clinical trials.
Methods
R-programs were developed to check data at either the
patient or site level, for fraud or data errors. These
included finding anomalous data patterns, digit prefer-
ence, rounding, incorrect dates (eg weekends/holidays),
values of variables too close or too far from the means,
odd correlation structures and extreme values or var-
iances. We applied these to 3 trials: (i) where data had
already been checked, (ii) an ongoing trial where our
findings could be checked in real-time, and (iii) where
data errors and fake patients were created.
Findings
T h ep r o g r a m sw e r ed e s i g n e dt ob er u na u t o m a t i c a l l y
and produce simple tables or figures. Few errors were
detected in the trial where data had already been
checked (as expected). Most data errors were found in
the two other trials. The programs were able to detect
data errors, as well as fabricated patients that we gener-
ated to have values that were too close to the multivari-
ate mean (fig. 1). They also detected centres that had
too few or too many serious adverse events (fig. 2). It
might be difficult to reliably apply some of the programs
to centres with few patients. Several patients that were
fabricated were not detected because the data did not
follow the assumptions used by the R-programs, or the
number of fabricated patients within a centre was too
small. Examples of the different output produced,
including easy-to-read diagrams and how they are inter-
preted, could be shown and discussed, along with their
strengths and limitations.
Conclusions
CSM appears to be a cost-effective and worthwhile
alternative to on-site monitoring. It can identify incor-
rect patient data, or centre where the data considered
together is too different to all other sites and therefore
should be reviewed. However, more research is needed
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Figure 1 Patient level data checks. Output for one site, in which
data were faked for 2 patients (shown in grey) by creating values
for several variables that were close to the mean of all patients
(which is more likely to occur if data were to be faked). Patients
with values which lie too close to the multivariate mean are shown
away from the others and were picked up (and circled in red) by
the program.
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Figure 2 Site level data checks. The y-axis represents the SAE rate
per site, allowing for time in the trial by patients. The lowest 10% of
SAE rates are shown as black squares. The circled observation is for
a site where data were faked so that the site had too few SAEs,
compared to the average for all sites (horizontal line). Sites in the
bottom right hand corner have lower than expected SAE rates but
relatively large numbers of patients, so could have on-site
monitoring checks.
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